If you’ve had your eye off the biotech sector recently because it doesn’t directly involve gold or cannabis, you’re missing out on one of the better casinos out there. For the high risk, high reward investor, nothing is quite like the thrill of correctly picking when a long, drawn out, US Food and Drug Administration process of approving a new drug finally gets over the line.
Resverlogix (RVX.T), Sirona Biochem (SBM.V), Sernova (SVA.V): 3 Canadian biotechs tackle a $330 billion health crisis
A Harvard University Study calculates the economic burden from diabetes at about $1.3 trillion, or 1.8% of global GDP.
With offices in 41 countries, 2.8 million members and a patriarchal structure, Greenpeace has global revenue of USD $300 million. Its most successful fundraising catalysts have been images of beautiful animals about to be slaughtered.
Sometimes when a public company is being quiet, the only way to figure out what they’re up to is to connect dots and assess risk. Stony Hill Corporation (STNY.OTC) is one company in that category.
Food safety is major concern for both producers and distributors, so it’s no surprise that the global food safety testing space is expected to be worth $8.0 billion by 2021. Lexagene (LXG.V) seeks to take commercial pathogen detection to a whole new level with its groundbreaking tech and company President, Daryl Rebeck, explains the how it works and what it could mean for investors. See for yourself. Watch live video from EquityDotGuru on www.twitch.tv
I remember the first time BlueOcean NutraSciences (BOC.V) came to my boardroom. They were amped over something that, they were certain, was going to turn the nutritional oil world on its ear.
You’ve got to give credit to Vinergy Resources (VIN.C), AKA MJ Biopharma, they said they were going to have plenty of news over the coming months, and they’ve definitely delivered.
Vinergy Resources (VIN.C) may still sound like a mining company, but the innovative CBD product development house acquiring MJ Biopharma is neck deep in its push toward establishing legit clinical trials for cannabidiol-related therapeutics.
In the spirit of ‘where are they now’ day comes another in my trilogy of companies I used to write about a lot, that I stopped writing about as they went into hiberation/preparation/organization mode, that have come out swinging in the last week or so.
Biotech flailer Hemostemix (HEM.V) took a punch to its distended gut today as a sell-off of the embattled stock cut the share price of the company by nearly half, at the time of writing.